LTX-109

CAS 1166254-80-3 1 current recordSmall Molecule

Who holds supplier records for LTX-109? 1 organisation holds a current record for LTX-109: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: Norway (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 11 Nov 2026. How we read these records

Cite as: PharmaTek, “LTX-109: DMF and CEP holder records”, record as of 11 Nov 2026, pharmatek.co.uk/directory/api/ltx-109

Reading the evidence

  • One current record

    One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.

  • No company-level GMP certificate matched

    No current EU or UK GMP certificate was matched to these organisations. That is not a negative finding; ask each candidate for its certificate and latest inspection outcome.

Current records (1)

Organisations holding an active US FDA Type II Drug Master File or a CEP for LTX-109. Country is the organisation's recorded country, not necessarily the manufacturing site.

  • AMICOAT AS
    Active DMF 41560 · latest filing Apr 2025
    Norway
Need LTX-109 sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Overview

LTX-109 is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1817968).

Chemical identity

IUPAC name
(2S)-2-amino-5-(diaminomethylideneamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide
Canonical SMILES
CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C
InChIKey
ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
Synonyms
Ltx 109, Ltx-109, LTX109, Voxvoganan, CHEBI:77752, RefChem:154172, Lytixar, AMC-109, VOXVOGANAN [INN], orb1986904, LTX 109 [WHO-DD], GTPL13759

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for LTX-109?

1 organisation holds an active US FDA Type II Drug Master File or a CEP for LTX-109: AMICOAT AS (Norway). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which LTX-109 Drug Master Files are active?

AMICOAT AS (DMF 41560). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

How do I qualify a LTX-109 supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply LTX-109?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.